Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)
2020
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
10
Citations
NaN
KQI